ArticleJournal of clinical microbiology2014
Global improvement in genotyping of human papillomavirus DNA: the 2011 HPV LabNet International Proficiency Study.
Article in Journal of clinical microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- HPV genotyping agreement between paired cervical cytological sample and biopsy across lesion severity and vaccination.Virology journal · 2025Trial
- Randomised study shows that repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology.British journal of cancer · 2018Trial
- Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study.BMC infectious diseases · 2016Trial
- Global Performance of Human Papillomavirus Typing, Screening, and Evaluation As Assessed Using Proficiency Panels Traceable to International Standards: A Retrospective Analysis, 2008-2024.Journal of medical virology · 2026Article
- International Collaborative Study on Human Papillomavirus Analytical Thresholds for Sensitivity and Specificity in Cervical Screening.Journal of medical virology · 2026Article
- Human Papillomavirus Primary Screening and Collaboration in Quality Assurance Work between Laboratories.Acta cytologica · 2026Review
- HPV, APOBEC3B, and the origins of breast cancer: a narrative review and perspectives on novel mechanisms.Frontiers in oncology · 2025Review
- A human papillomavirus whole genome plasmid repository: A resource for HPV DNA quality control reagents.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2023Article
- Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Article
- Human papillomavirus genotype concordance between Anyplex II HPV28 and linear array HPV genotyping test in anogenital samples.Journal of medical virology · 2022Article
- A comprehensive HPV-STI NGS assay for detection of 29 HPV types and 14 non-HPV sexually transmitted infections.Infectious agents and cancer · 2022Article
- The routine use of LCD-Array hybridisation technique for HPV subtyping in the diagnosis of penile carcinoma compared to other methods.BMC urology · 2022Article
- Nested PCR followed by NGS: Validation and application for HPV genotyping of Tunisian cervical samples.PloS one · 2021Article
- Article
- Article
- Universal human papillomavirus typing by whole genome sequencing following target enrichment: evaluation of assay reproducibility and limit of detection.BMC genomics · 2019Article
- Article
- Analytical Evaluation of the Human Papillomavirus HPV DNA Array E1-Based Genotyping Assay.Intervirology · 2019Article
- Inverted papilloma of the conjunctiva.BMJ open ophthalmology · 2019Article
- Comparison of PapilloCheck and Linear Array to Detect and Differentiate Human Papillomaviruses in Cervical and Tonsillar Smears from Females with Cervical Intraepithelial Lesions.European journal of microbiology & immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate and internationally comparable human papillomavirus (HPV) DNA genotyping is essential for HPV vaccine research and for HPV surveillance. The HPV Laboratory Network (LabNet) has designed international proficiency studies that can be issued regularly and in a reproducible manner. The 2011 HPV genotyping proficiency panel contained 43 coded samples composed of purified plasmids of 16 HPV types (HPV6, -11, -16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, -68a, and -68b) and 3 extraction controls. Tests that detected 50 IU of HPV16 and HPV18 and 500 genome equivalents for the other 14 HPV types in both single and multiple infections were considered proficient. Ninety-six laboratories worldwide submitted 134 data sets. Twenty-five different HPV genotyping assay methods were used, including the Linear Array, line blot/INNO-LiPA, PapilloCheck, and PCR Luminex assays. The major oncogenic HPV types, HPV16 and HPV18, were proficiently detected in 97.0% (113/116) and 87.0% (103/118) of the data sets, respectively. In 2011, 51 data sets (39%) were 100% proficient for the detection of at least one HPV type, and 37 data sets (28%) were proficient for all 16 HPV types; this was an improvement over the panel results from the 2008 and 2010 studies, when <25 data sets (23% and 19% for 2008 and 2010, respectively) were fully proficient. The improvement was also evident for the 54 laboratories that had also participated in the previous proficiency studies. In conclusion, a continuing global proficiency program has documented worldwide improvement in the comparability and reliability of HPV genotyping assay performances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.